Leerink Partners Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price target lowered by equities research analysts at Leerink Partners from $30.00 to $23.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ price target indicates a potential upside of 127.50% from the stock’s current price.

KROS has been the topic of several other research reports. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. HC Wainwright reiterated a “buy” rating on shares of Keros Therapeutics in a research report on Tuesday. Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $20.83.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $10.11 on Tuesday. The firm has a fifty day moving average of $10.68 and a two-hundred day moving average of $12.59. The firm has a market cap of $200.08 million, a P/E ratio of -3.36 and a beta of 0.99. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.20). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. On average, sell-side analysts expect that Keros Therapeutics will post -5.19 EPS for the current year.

Insider Activity

In other news, Director Julius Knowles sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director owned 10,958 shares in the company, valued at approximately $117,579.34. This represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director directly owned 9,767 shares in the company, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,425 shares of company stock valued at $89,994. 12.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company lifted its holdings in shares of Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after purchasing an additional 988 shares during the last quarter. UBS Group AG boosted its position in shares of Keros Therapeutics by 1.1% in the 3rd quarter. UBS Group AG now owns 103,864 shares of the company’s stock valued at $1,643,000 after purchasing an additional 1,091 shares during the period. Strs Ohio increased its stake in Keros Therapeutics by 3.9% in the 4th quarter. Strs Ohio now owns 29,300 shares of the company’s stock worth $597,000 after purchasing an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after buying an additional 1,166 shares during the period. Finally, Financial Management Professionals Inc. purchased a new stake in Keros Therapeutics during the fourth quarter valued at about $29,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.